Articles

Find an Article

Filter articles

Showing 11 to 20 of 737 results

Will authorised biologics deter biosimilars? Utilising JFTC’s expertise in drug pricing

Japan08-03-2022Takanori Abe

Should the MHLW and CSIMC consider competition in drug pricing, it would be necessary to formulate systems to utilise the expertise of a competition expert, namely the Japan Fair Trade Commission, says Takanori Abe of Abe & Partners.

SurgiSil: Lip implant case shows looks can be deceiving

US03-03-2022Elizabeth Ferrill

A seemingly small decision by the US Court of Appeals for the Federal Circuit could have a big impact on owners of design patents, explains Elizabeth Ferrill of Finnegan.

When alliances fail, is arbitration the answer?

24-02-2022

The global pandemic has increased collaboration and a new wave of disputes is likely. Arbitration is well placed to help, argue Kate Davies McGill, Gaela Gehring Flores and Paul Keller of Allen & Overy

UN International Day of Women and Girls in Science: a perspective

International10-02-2022Chiara Banas

Chiara Banas, patent scientist at EIP, queries the gender gap in life sciences, and shares how her own experiences could prefigure change.

Why mentorship matters

International25-01-2022Muireann Bolger

Effective support and guidance can achieve greater diversity in life sciences, say general counsel from Bristol Myers Squibb, AstraZeneca, The Chemours Company and Eli Lilly.

Pandemic blues: the global approach to COVID-related IP

US20-01-2022Matthew Howell and Lauren Griffin

While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

A guide for life sciences entrepreneurs

International22-12-2021Chad Shear

Small companies face the same long product cycles and upfront costs as the big players but have different IP challenges, explains Chad Shear of Fish & Richardson.

Psychedelics: from fungi and plants to patents

US30-09-2021Gretchen Temeles & Timothy Schlidt

With the significant growth of cannabinoid IP in the past few years, eyes are now on the emerging psychedelics market as the next frontier for IP protection. Gretchen Temeles of Hiller and Timothy Schlidt of Palo Santo Ventures discuss the issues.

Mexico: New hurdles for plant rights owners

Mexico23-09-2021Corina Silva

Mexico’s updated IP laws seek to avoid the patentability of plants obtained by essentially biological processes—creating issues for plant rights owners, explains Corina Silva of Uhthoff, Gómez Vega & Uhthoff.

Amendments to Chinese Patents Law for the Life Sciences

China09-09-2021Keith Haddaway and Christopher Loh

Recent changes to patent law in China sees registration, review and litigation fall in line with established international IP systems, say Venable partners Keith Haddaway and Christopher Loh.

Showing 11 to 20 of 737 results

LSIPR